Sanyuan Biology released its 2026 interim report, with total operating revenue of 429 million yuan and net profit attributable to the parent of 50.3976 million yuan, a decrease of 12.32% compared with the same period last year. The company's net cash inflow from operating activities was 73.6372 million yuan, its asset-liability ratio was 6.46%, its gross margin was 17.59%, and diluted earnings per share was 0.25 yuan. The number of shareholders was 14,400, and the top ten shareholders held 64.74% of the total share capital.
Shandong Sanyuan Biotechnology Co.Ltd.Net profit fell 12.32% year-on-year in the interim report.
